Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Moonbow-112 (also known as Demecan Core Moonbow-112) is an unirradiated medical cannabis flower product developed and distributed by DEMECAN in Germany. It is derived from the 'Moonbow 112 IX' cultivar, an Indica-dominant hybrid strain originally bred by Archive Seed Bank from a cross of Zkittlez and Do-Si-Dos. The product is available in different THC concentrations, such as approximately 23% (Demecan Core Moonbow-112 23:01) and 27% (Demecan Core Moonbow-112 27:01), with less than 1% CBD. It is prescribed for the management of various conditions including chronic pain, inflammation, and stress, exerting its therapeutic effects primarily through the activation of cannabinoid receptors CB1 and CB2 by its active cannabinoid components, such as tetrahydrocannabinol (THC).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Moonbow-112.